GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTL) » Definitions » EPS without NRI

Artelo Biosciences (Artelo Biosciences) EPS without NRI : $-3.36 (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Artelo Biosciences EPS without NRI?

Artelo Biosciences's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-1.04. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.36.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 43.90% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 38.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Artelo Biosciences's EPS without NRI or its related term are showing as below:

ARTL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -387   Med: -74.2   Max: 45.1
Current: 43.9

During the past 10 years, Artelo Biosciences's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 45.10% per year. The lowest was -387.00% per year. And the median was -74.20% per year.

ARTL's 3-Year EPS without NRI Growth Rate is ranked better than
88.19% of 1304 companies
in the Biotechnology industry
Industry Median: 5.45 vs ARTL: 43.90

Artelo Biosciences's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.99. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.14.

Artelo Biosciences's EPS (Basic) for the three months ended in Dec. 2023 was $-0.99. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.14.


Artelo Biosciences EPS without NRI Historical Data

The historical data trend for Artelo Biosciences's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences EPS without NRI Chart

Artelo Biosciences Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.95 -19.02 -5.97 -3.63 -3.36

Artelo Biosciences Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.23 -0.80 -0.63 -0.89 -1.04

Competitive Comparison of Artelo Biosciences's EPS without NRI

For the Biotechnology subindustry, Artelo Biosciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artelo Biosciences's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artelo Biosciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Artelo Biosciences's PE Ratio without NRI falls into.



Artelo Biosciences EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Artelo Biosciences  (NAS:ARTL) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Artelo Biosciences EPS without NRI Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Artelo Biosciences (Artelo Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
Executives
Gregory D. Gorgas director, officer: See Remarks 888 PROSPECT, SUITE 210, LA JOLLA CA 92037
Tamara A Seymour director C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Gregory Reyes director 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Matsui Connie director 3030 CALLAN RD, SAN DIEGO CA 92121
John W Beck director C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067
Robert Martin Emanuele director
David J Moss 10 percent owner C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Georgia Erbez director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Steven Kelly director C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Douglas Blayney director C/O ARTELO BIOSCIENCES, INC., 888 PROSPECT ST, SUITE 210, LA JOLLA CA 92037
Peter Michael O'brien 10 percent owner C/O ARTELO BIOSCIENCES, INC., 888 PROSPECT ST, SUITE 210, LA JOLLA CA 92037

Artelo Biosciences (Artelo Biosciences) Headlines

From GuruFocus